ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
|Articles|June 30, 2020
Avantor Expands its New Jersey Innovation Center
Author(s)BioPharm International Editors
The site can now support customized product and bioprocess development and custom cell and gene therapy reagent manufacturing.
Advertisement
Avantor announced on June 30, 2020 that it has expanded its Bridgewater, NJ innovation center to support bioprocessing capabilities for protein science, monoclonal antibodies (mAbs), and cell and gene therapy.
The site can now offer customized product and bioprocess development and custom cell and gene therapy reagent manufacturing, a company press release said. The company aims to minimize contamination and variability for cell and gene therapy, mAbs, and vaccines, using high purity products, single-use solutions, and small volume cGMP reagents in single-use bags.
"Innovation is about solving customer problems in a rapidly progressing biotechnology environment using contemporary technologies and thinking," said Dr. Ger Brophy, executive vice-president, Biopharma Production at Avantor, in the press release. "We collaborate with our customers from their initial discovery and development activities through scale-up and commercialization. Our solutions support industry downward cost pressure by emphasizing supply chain efficiency and improving production process performance."
Source:
Advertisement
Related to this article
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5